Download PDF
Pharmacopsychiatry 2001; 34(1): 27-32
DOI: 10.1055/s-2001-15194
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Serum Levels of Sulpiride Enantiomers after Oral Treatment with Racemic Sulpiride in Psychiatric Patients: a Pilot Study[1]

M. J. Müller, S. Härtter, D. Köhler, Ch. Hiemke
  • Department of Psychiatry, University of Mainz, Germany
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Sulpiride (SULP), a substituted benzamide with high selectivity for D2-like dopamine receptors, has a chiral structure and is used in most countries as the racemate. In an open pilot study, we investigated 26 inpatients (13 female, 13 male) with schizophrenic or depressive disorder treated with SULP (mean daily dosage 64 - 1062 mg) administered orally, either as a monotherapy or as an add-on treatment to a stable and unchanged medication for 3 - 60 days. Serum levels of total SULP and of its enantiomers were measured by high-performance liquid chromatography (HPLC) procedures. Clinically relevant indicators of hepatic and renal function as well as retrospectively assessed clinical outcome parameters were correlated with serum levels of racemic SULP, L-SULP, D-SULP, and the L : D-SULP ratio. A significant correlation between mean daily dosage and serum levels of SULP, L-SULP, and D-SULP emerged (p < 0.05) which was not influenced by age, gender, diagnosis, hepatic, or renal function. The ratio of L : D-SULP serum levels was < 1 (range 0.66 - 0.97) in all patients. A slight negative correlation between CGI improvement and the ratio of L : D-SULP (p < 0.10) and a positive correlation between racemic SULP concentrations and side-effects at endpoint was found (p < 0.05).

1 Preliminary results of the present paper were presented at the XI. Congress of the World Psychiatric Association, September 1999, Hamburg, Germany

References

  • 1 Benkert O, Holsboer F. Effect of sulpiride in endogenous depression.  Acta Psychiatr Scand. 1984;  311 43-48
    PubMedGoogle Scholar
  • 2 Bressolle F, Faure-Jeantis A. Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans.  J Pharm Sci. 1992;  81 26-32
    PubMedGoogle Scholar
  • 3 Collegium Internationale Psychiatriae Scalarum (CIPS). Weinheim; Beltz 1988
    Google Scholar
  • 4 Crescimanno G, Sorbera F, Emmi A, Amato G. Inhibitory effect of A10 dopaminergic neurons of the ventral tegmental area on the orienting response evoked by acoustic stimulation in the cat.  Brain Res Bull. 1998;  45 61-65
    CrossrefPubMedGoogle Scholar
  • 5 Dahl S G. Pharmacokinetics of neuroleptic drugs and the utility of plasma level monitoring.  Psychopharmacol Ser. 1988;  5 34-46
    PubMedGoogle Scholar
  • 6 Dahl S G. Plasma level monitoring of antipsychotic drugs. Clinical utility.  Clin Pharmacokinet. 1986;  11 36-61
    PubMedGoogle Scholar
  • 7 Edwards J G, Alexander J R, Alexander M S, Gordon A, Zutchi T. Controlled trial of sulpiride in chronic schizophrenia.  Br J Psychiatry. 1980;  137 522-529
    PubMedGoogle Scholar
  • 8 Gerlach J, Behnke K, Heltberg J, Munk-Anderson E, Nielsen H. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and serum concentrations.  Br J Psychiatry. 1983;  147 283-288
    PubMedGoogle Scholar
  • 9 Lane R M, Baker G B. Chirality and drugs used in psychiatry: nice to know or need to know?.  Cell Mol Neurobiol. 1999;  19 355-372
    CrossrefPubMedGoogle Scholar
  • 10 Maier W, Benkert O. Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies.  Psychopharmacology. 1994;  115 495-501
    PubMedGoogle Scholar
  • 11 Mauri M C, Bitetto A, Fabiano L, Laini V, Steinhilber C, Fornier M, Rafique F. Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs.  Prog Neuropsychopharmacol Biol Psychiatry. 1999;  23 43-54
    Google Scholar
  • 12 Mucci A, Nolfe G, Maj M. Levosulpiride: a review of its clinical use in psychiatry.  Pharmacol Res. 1995;  31 95-101
    PubMedGoogle Scholar
  • 13 Polatti F. Sulpiride isomers and milk secretion in puerperium.  Clin Exp Obstet Gynecol. 1982;  9 144-147
    PubMedGoogle Scholar
  • 14 Rao V A, Bailey J, Bishop M, Coppen A. A clinical and pharmacodynamic evaluation of sulpiride.  Psychopharmacology. 1981;  73 77-80
    CrossrefPubMedGoogle Scholar
  • 15 Rietbrock S, Merz P G, Fuhr U, Harder S, Marschner J P, Loew D, Biehl J. Absorption behavior of sulpiride described using Weibull functions.  Int J Clin Pharmacol Ther. 1995;  33 299-303
    PubMedGoogle Scholar
  • 16 Russell V, de Villiers A, Sagvolden T, Lamm M, Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder - the spontaneously hypertensive rat.  Brain Res. 1995;  676 343-351
    CrossrefPubMedGoogle Scholar
  • 17 Rüther E, Degner D, Munzel U, Brunner E, Lenhard G, Biehl J, Vogtle-Junkert U. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial.  Pharmacopsychiat. 1999;  32 127-135
    PubMedGoogle Scholar
  • 18 Seeman P. Dopamine receptors: Clinical correlates. In: Bloom FE, Kupfer DJ, editors Psychopharmacology: The fourth generation of progress. New York; Raven Press 1995: 295-302
    Google Scholar
  • 19 Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.  Br J Psychiatry. 1995;  171 569-573
    PubMedGoogle Scholar
  • 20 Tokunaga H, Kudo K, Imamura T, Jitsufuchi N, Ohtsuka Y, Ikeda N. Plasma concentrations of antipsychotic drugs in psychiatric inpatients.  Nippon Hoigaku Zasshi. 1997;  51 417-422
    PubMedGoogle Scholar
  • 21 Tokunaga H, Kudo K, Jitsufuchi N, Ohtsuka Y, Imamura T. Sensitive determination of sulpiride in human plasma by high-performance liquid chromatography.  J Chromatogr B Biomed Sci Appl. 1997;  691 203-207
    CrossrefPubMedGoogle Scholar
  • 22 Vergoni A V, Forgione A, Bertolini A. Chronic administration of l-sulpiride at non-neuroleptic doses reduces the duration of immobility on experimental models of “depression-like” behavior.  Psychopharmacology. 1995;  121 279-281
    PubMedGoogle Scholar
  • 23 Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action.  Int Clin Psychopharmacol. 1997;  12 (Suppl 3) S7-S14
    PubMedGoogle Scholar

1 Preliminary results of the present paper were presented at the XI. Congress of the World Psychiatric Association, September 1999, Hamburg, Germany

Dr. Matthias J. Müller

Department of Psychiatry
University of Mainz

Untere Zahlbacher Straße 8

55131 Mainz

Germany

Phone: ++49-17-2920

Fax: ++49-17-6690

Email: mjm@mail.psychiatrie.klinik.uni-mainz.de

      >